These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 20638755

  • 1. Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay.
    Al-Sha'er MA, Taha MO.
    Eur J Med Chem; 2010 Sep; 45(9):4316-30. PubMed ID: 20638755
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.
    Habash M, Taha MO.
    Bioorg Med Chem; 2011 Aug 15; 19(16):4746-71. PubMed ID: 21788139
    [Abstract] [Full Text] [Related]

  • 4. Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads.
    Shahin R, Taha MO.
    Bioorg Med Chem; 2012 Jan 01; 20(1):377-400. PubMed ID: 22112539
    [Abstract] [Full Text] [Related]

  • 5. Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation.
    Al-Nadaf AH, Taha MO.
    J Mol Graph Model; 2011 Apr 01; 29(6):843-64. PubMed ID: 21376648
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
    Kim MK, Min J, Choi BY, Lim H, Cho YH, Lee CH.
    J Microbiol Biotechnol; 2007 Oct 01; 17(10):1712-6. PubMed ID: 18156791
    [Abstract] [Full Text] [Related]

  • 9. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
    Yu H, Wang Z, Zhang L, Zhang J, Huang Q.
    Bioorg Med Chem Lett; 2007 Apr 15; 17(8):2126-33. PubMed ID: 17306530
    [Abstract] [Full Text] [Related]

  • 10. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
    Abu Hammad AM, Taha MO.
    J Chem Inf Model; 2009 Apr 15; 49(4):978-96. PubMed ID: 19341295
    [Abstract] [Full Text] [Related]

  • 11. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.
    Al-Masri IM, Mohammad MK, Taha MO.
    ChemMedChem; 2008 Nov 15; 3(11):1763-79. PubMed ID: 18989859
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors.
    Dong X, Yan J, Du L, Wu P, Huang S, Liu T, Hu Y.
    J Mol Graph Model; 2012 Jul 15; 37():77-86. PubMed ID: 22622012
    [Abstract] [Full Text] [Related]

  • 14. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
    Medina-Franco JL, Giulianotti MA, Yu Y, Shen L, Yao L, Singh N.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4634-8. PubMed ID: 19604696
    [Abstract] [Full Text] [Related]

  • 15. Application of Free-Wilson selectivity analysis for combinatorial library design.
    Sciabola S, Stanton RV, Johnson TL, Xi H.
    Methods Mol Biol; 2011 Aug 15; 685():91-109. PubMed ID: 20981520
    [Abstract] [Full Text] [Related]

  • 16. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
    Vyas VK, Ghate M, Goel A.
    J Mol Graph Model; 2013 May 15; 42():17-25. PubMed ID: 23507201
    [Abstract] [Full Text] [Related]

  • 17. Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.
    Taha MO, Atallah N, Al-Bakri AG, Paradis-Bleau C, Zalloum H, Younis KS, Levesque RC.
    Bioorg Med Chem; 2008 Feb 01; 16(3):1218-35. PubMed ID: 17988876
    [Abstract] [Full Text] [Related]

  • 18. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
    Huang S, Li R, Connolly PJ, Emanuel S, Middleton SA.
    Bioorg Med Chem Lett; 2006 Sep 15; 16(18):4818-21. PubMed ID: 16870444
    [Abstract] [Full Text] [Related]

  • 19. Multiple pharmacophore models combined with molecular docking: a reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity.
    Chen Z, Tian G, Wang Z, Jiang H, Shen J, Zhu W.
    J Chem Inf Model; 2010 Apr 26; 50(4):615-25. PubMed ID: 20353193
    [Abstract] [Full Text] [Related]

  • 20. Structure-aided optimization of kinase inhibitors derived from alsterpaullone.
    Kunick C, Zeng Z, Gussio R, Zaharevitz D, Leost M, Totzke F, Schächtele C, Kubbutat MH, Meijer L, Lemcke T.
    Chembiochem; 2005 Mar 26; 6(3):541-9. PubMed ID: 15696597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.